The long-term survival of a patient with neuroblastoma suggests the personalized cancer treatment may work for solid tumors, not just blood cancers.

Helen Heslop and colleagues conducted a phase 1 clinical trial involving 19 children with neuroblastoma, between 2004 and 2009, during which they tested T cells that were engineered to recognize ...

Among 19 neuroblastoma patients treated with CAR T-cell therapy, eight survived more than 5 years after infusion, including five with follow-up of more than 13 years, reported Helen Heslop ...

What the data say When the Texas neuroblastoma study began in 2004, CAR-T-cell therapy was still a bit of a wild idea, says Helen Heslop, an immunotherapy researcher at Baylor College of Medicine ...

so that she’s grown up and is leading a normal life,” Professor Helen Heslop, co-author of the research from Houston’s Baylor College of Medicine and the director of the Center for Cell and ...

“Our findings suggest that even with this early study some patients can have long-lasting benefit,” said corresponding author Dr. Helen Heslop, director of the Center for Cell and Gene Therapy, deputy ...

Professor Helen Heslop, who led the trial, said: 'It's nice to have such long-term follow-up and to see that even if it was a very early CAR T-cell – and there's been a lot of work to make them ...

Helen Heslop, a professor of medicine and paediatrics at Baylor College, and her colleagues had conducted a safety and preliminary efficacy trial of CAR-T therapy on 19 children with neuroblastoma ...

so that she’s grown up and is leading a normal life,” Professor Helen Heslop, co-author of the research from Houston’s Baylor College of Medicine and the director of the Center for Cell and Gene ...